Literature DB >> 19931163

CD40 ligand deficiency: neurologic sequelae with radiographic correlation.

Shrinivas Bishu1, Deepak Madhavan, Phillip Perez, Lucy Civitello, Shuying Liu, Margaret Fessler, Steven M Holland, Ashish Jain, Maryland Pao.   

Abstract

Patients with CD40 ligand deficiency are susceptible to central nervous system infections, but to date the neurologic progression or long-term outcome of central nervous system complications have not been reported in detail. Characterizing the central nervous system complications of immune deficiencies can lead to the identification of new pathogens. For this study, clinical data were reviewed on patients with both CD40 ligand deficiency and neurodegeneration, identified from a larger cohort of 31 patients. Five patients had progressive neurologic and cognitive decline in the absence of clinical signs of acute fulminant encephalitis, with anatomic brain abnormalities and high mortality (60%). Despite multiple evaluations, no pathogens were identified in four patients, all of whom were on standard intravenous immunoglobulin therapy at illness presentation. This clinical phenotype of progressive decline without acute fulminant encephalitis is similar to chronic enteroviral encephalitis in X-linked agammaglobulinemia, another condition with severe humoral immune defects. Whether infection secondary to subtherapeutic levels of central nervous system immunoglobulin G (IgG), inadequately protective levels of serum IgG, or impaired CD40 ligand-dependent IgG-independent antiviral responses contributed remains undetermined. Emerging gene-chip techniques applied in patients with primary immune deficiencies may identify heretofore unknown viruses. Prospective neurocognitive and evaluation of patients with CD40 ligand deficiency may identify affected patients before overt clinical signs appear.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19931163      PMCID: PMC3130593          DOI: 10.1016/j.pediatrneurol.2009.07.003

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  40 in total

1.  Microarray-based detection and genotyping of viral pathogens.

Authors:  David Wang; Laurent Coscoy; Maxine Zylberberg; Pedro C Avila; Homer A Boushey; Don Ganem; Joseph L DeRisi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-12       Impact factor: 11.205

2.  Progressive neurodegeneration in patients with primary immunodeficiency disease on IVIG treatment.

Authors:  Ulrike H M Ziegner; Roger H Kobayashi; Charlotte Cunningham-Rundles; Teresa Español; Anders Fasth; Anna Huttenlocher; Paul Krogstad; Lars Marthinsen; Luigi D Notarangelo; Srdjan Pasic; Christian H L Rieger; Peter Rudge; Raman Sankar; Ann O Shigeoka; E Richard Stiehm; Kathleen E Sullivan; A David Webster; Hans D Ochs
Journal:  Clin Immunol       Date:  2002-01       Impact factor: 3.969

3.  Treatment of potentially life-threatening enterovirus infections with pleconaril.

Authors:  H A Rotbart; A D Webster
Journal:  Clin Infect Dis       Date:  2001-01-15       Impact factor: 9.079

4.  The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients.

Authors:  Jerry A Winkelstein; Mary C Marino; Hans Ochs; Ramsey Fuleihan; Paul R Scholl; Raif Geha; E Richard Stiehm; Mary Ellen Conley
Journal:  Medicine (Baltimore)       Date:  2003-11       Impact factor: 1.889

5.  Enteroviral infections in primary immunodeficiency (PID): a survey of morbidity and mortality.

Authors:  E Halliday; J Winkelstein; A D B Webster
Journal:  J Infect       Date:  2003-01       Impact factor: 6.072

6.  CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes.

Authors:  Z Lu; L Yuan; X Zhou; E Sotomayor; H I Levitsky; D M Pardoll
Journal:  J Exp Med       Date:  2000-02-07       Impact factor: 14.307

7.  A newly discovered human pneumovirus isolated from young children with respiratory tract disease.

Authors:  B G van den Hoogen; J C de Jong; J Groen; T Kuiken; R de Groot; R A Fouchier; A D Osterhaus
Journal:  Nat Med       Date:  2001-06       Impact factor: 53.440

8.  Viral discovery and sequence recovery using DNA microarrays.

Authors:  David Wang; Anatoly Urisman; Yu-Tsueng Liu; Michael Springer; Thomas G Ksiazek; Dean D Erdman; Elaine R Mardis; Matthew Hickenbotham; Vincent Magrini; James Eldred; J Phillipe Latreille; Richard K Wilson; Don Ganem; Joseph L DeRisi
Journal:  PLoS Biol       Date:  2003-11-17       Impact factor: 8.029

9.  Predominance of rhinovirus in the nose of symptomatic and asymptomatic infants.

Authors:  Inesz van Benten; Laurens Koopman; Bert Niesters; Wim Hop; Barbara van Middelkoop; Leon de Waal; Kees van Drunen; Albert Osterhaus; Herman Neijens; Wytske Fokkens
Journal:  Pediatr Allergy Immunol       Date:  2003-10       Impact factor: 6.377

Review 10.  Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency.

Authors:  Melvin Berger
Journal:  Immunol Allergy Clin North Am       Date:  2008-05       Impact factor: 3.479

View more
  3 in total

Review 1.  The role of tumor necrosis factor receptor superfamily members in mammalian brain development, function and homeostasis.

Authors:  Jason P Twohig; Simone M Cuff; Audrey A Yong; Eddie C Y Wang
Journal:  Rev Neurosci       Date:  2011-08-24       Impact factor: 4.353

2.  Distinct plasma immune signatures in ME/CFS are present early in the course of illness.

Authors:  Mady Hornig; José G Montoya; Nancy G Klimas; Susan Levine; Donna Felsenstein; Lucinda Bateman; Daniel L Peterson; C Gunnar Gottschalk; Andrew F Schultz; Xiaoyu Che; Meredith L Eddy; Anthony L Komaroff; W Ian Lipkin
Journal:  Sci Adv       Date:  2015-02       Impact factor: 14.136

Review 3.  Cryptococcal Meningitis and Post-Infectious Inflammatory Response Syndrome in a Patient With X-Linked Hyper IgM Syndrome: A Case Report and Review of the Literature.

Authors:  Lorenza Romani; Peter Richard Williamson; Silvia Di Cesare; Gigliola Di Matteo; Maia De Luca; Rita Carsetti; Lorenzo Figà-Talamanca; Caterina Cancrini; Paolo Rossi; Andrea Finocchi
Journal:  Front Immunol       Date:  2021-07-15       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.